Antibody-interleukin 2 fusion proteins: A new approach to cancer therapy

Journal of Clinical Laboratory Analysis

Volumn 10, Issue 3, 1996, Pages 160-166

  Reisfeld, Ralph A ^a   Gillies, Stephen D ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Fuji ImmunoPharmaceuticals Corp   (United States)

Author keywords

cytokine fusion; immunotherapy; melanoma and neuroblastoma; recombinant antibodies

Indexed keywords

CYTOKINE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANIMAL MODEL; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER METASTASIS; LUNG SMALL CELL CANCER; MELANOMA; NEUROBLASTOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; SARCOMA; SOLID TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MELANOMA; MICE; NEOPLASMS; NEUROBLASTOMA; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0029990088     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1996)10:3<160::AID-JCLA9>3.0.CO;2-F     Document Type: Review

References (34)

1. Riethmuller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R. Höffken G, Gruber R, Pichlmaier H, Hirche H, Pichelmair R: Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1172-1183, 1994.
2. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, LoBuglio AF: Phase I trial of the murine monoclonal anti-GD2 antibody 14.G2a in metastatic melanoma. Cancer Res 52:4342-4347, 1992.
3. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, Kasi LP, Bhadkamkar V, Fritsche HA, Benjamin RS, Legha SS, Ater JL, Jaffe N, Itoh K, Ross MI, Bucana CD, Thompson L, Cheung L, Rosenblum MG: Phase I trial of murine monoclonal antibody 14.G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 12:184-193, 1994.
4. Handgretinger R, Baader P, Dopfer R, Klingbiel T, Reuland P, Reisfeld RA, Treuner J, Niethammer D: A phase I study of neuroblastoma with the anti-ganglioside GD2 study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 35:199-204, 1992.
5. Handgretinger R, Anderson K, Lang P, Dopfer R, Klingbiel T, Schrappe M, Reuland P, Gillies SD, Reisfeld RA, Niethammer D: A phase I study of human/mouse chimeric anti-ganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A:261-267, 1995.
6. Winter G, Milstein C: Man-made antibodies.Nature 349:293-299, 1991.
7. Wright A, Shin S-U, Morrison SL: Genetically engineered antibodies: Progress and prospects. Critical Rev Immunol 12:125-168, 1992.
8. Pai LH. Pastan I: Immunotoxins and recombinant toxins for cancer treatment. In: Important Advances in Oncology. VT DeVita, S Hellman, SA Rosenberg, eds. Lippincott, Philadelphia, 1994, p 3-19.
9. Brinkmann U, Pastan I: Immunotoxins against cancer. Biochim Biophys Acta 1198:27-45, 1994.
10. Schlom J: Monoclonal antibodies in cancer therapy. In Biologic Therapy of Cancer, 2nd ed. VT De Vita, S Hellman, SA Rosenberg, eds Lippincott, Philadelphia, 1995, p 507-521.
11. Ashkenazi A, Capon DI, Ward RHR: Immunoadhesins. Intern Rev Immunol 10:219-227, 1993.
12. Smith RIF, Morrison SL: Recombinant polymeric IgG: An approach to engineering more potent antibodies. Bio Technol 12:683-688, 1994.
13. Tepper RI, Pattengale PK, Leder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503-510, 1989.
14. Pardoll DM: Cancer vaccines, Immunol Today 14:310-316, 1993.
15. Colombo MP, Fomi G: Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol Today 15:48-51, 1994.
16. Tao M-H, Levy R: Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma, Nature 362:755-758, 1993.
17. Reisfeld RA, Gillies SD: Recombinant antibody fusion proteins for cancer immunotherapy. In Current Topics in Microbiology and Immunology: Therapeutic Approaches for Metastasis Treatment. U Günthert, W Birchmeier, eds. Springer-Verlag, Heidelberg, 1996 (in press).
18. Burke F, Naylor NS, Davies B, Balkwill F: The cytokine wall chart. Immunol Today 14:165-170, 1993.
19. Gillies SD, Reilly EB, Lo K-M, Reisfeld RA: Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 89:1428-1432, 1992.
20. Mujoo K, Cheresh DA,Yang HM, Reisfeld RA: Disialoganglioside GD2 on human neuroblastoma: Target antigen for monoclonal antibody mediated cytolysis and suppression of tumor growth. Cancer Res 47:1098-1104, 1986.
21. Reisfeld RA, Cheresh DA: Human tumor antigens. In: Advances in Immunology. FJ Dixon, ed. Academic Press, New York, 1987. p 323-377.
22. Mujoo K, Kipps TJ, Yang HM, Cheresh DA, Wargalla U, Sander DJ, Reisfeld RA: Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal anti-ganglioside GD2 antibody 14.18. Cancer Res 49:2857-2861, 1989.
23. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-485, 1989.
24. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentraber DS, Weber JS, Parkinson DR, Seipp CA, Einhorn JD, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86:1159-1166, 1994.
25. Weil-Hillman G, Schell K, Segal DM, Hank JA, Sosman JA, Sondel PM: Activation of human T cells obtained pre- and post-interleukin-2 (IL2) therapy by anti-CD3 monoclonal antibody plus IL2: Implications for combined in vivo treatment. J Immunother 10:267-277, 1991.
26. Gillies SD, Young D, Lo K-M, Roberts S: Biological activity and in vivo clearance of anti-tumor antibody/cytokine fusion proteins. Biocanjugate Chem 4:230-235, 1993.
27. Gillies SD, Wesolowski JS, Lo K-M: Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing cells. J Immunol 146:1067-1071, 1991.
28. Mueller BM, Reisfeld RA, Gillies SD: Serum half-life and tumor localization of a chrmeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA 87:5702-5705, 1990.
29. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM: Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol Letters 39:91-99, 1994.
30. Favrot MC, Floret D, Negrier S, Cochat P, Bouffet E, Dacheng Z, Franks CR, Bijman T, Brunat-Mentigny M, Philip I, Philip T: Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation. Bone Marron Transplantation 4:499-504, 1989.
31. Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung NK, Sondel PM: Augmentation of antibody-dependent cell mediated cytotoxicity following in vivo therapy with interleukin 2. Cancer Res 50:5234-5239, 1990.
32. Hank JA, Surfus J, Gan F, Chew T-L, Hong R, Tans K, Reisfeld RA, Seeger RC, Reynolds CP, Bauer M, Wiersma S, Hammond D, Sondel PM: Treatment of neuroblastoma patients with anti-ganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15:29-37, 1994.
33. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA: A recombinant antibody interleukin-2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 91:9626-9630, 1994.
34. Takahashi H, Nakada T, Puisieus I: Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259:1460-1463, 1993.